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BACKGROUND: Histamine is released from mast cells by
immunologic  and  non-immunologic  stimuli  during
salivary  gland  inflammation,  regulating  salivary
secretion. The receptor-secretory mechanism has not
been studied in detail.
Aims:  The  studies  reported  were  directed  toward
elucidating  signal  transduction/second  messenger
pathways within the rat submandibular gland asso-
ciated  with  2-thiazolylethylamine  (ThEA)-induced
H1-receptor responses.
Materials  and  methods:  To  assess  the  H1 receptor
subtype expression in the rat submandibular gland, a
radioligand binding assay was performed. The study
also  included  inositolphosphates  and  cyclic  GMP
accumulation,  protein  kinase  C  and  nitric  oxide
synthase activities, and amylase release.
Results:  The  histamine  H1 receptor  subtype  is
expressed on the rat submandibular gland with high-
affinity binding sites. The ThEA effect was associated
with  activation  of  phosphoinositide-specific  phos-
pholipase C, translocation of protein kinase C, stim-
ulation of nitric oxide synthase activity and increased
production of cyclic GMP. ThEA stimulation of nitric
oxide synthase and cyclic GMP was blunted by agents
able to interfere with calcium movilization, while a
protein kinase C inhibitor was able to stimulate ThEA
action. On the other hand, ThEA stimulation evoked
amylase  release  via  the  H1  receptor  but  was  not
followed  by  the  L-arginine/nitric  oxide  pathway
activation.
Conclusions: These results suggest  that, apart from
the effect of ThEA on amylase release, it also appears
to  be  a  vasoactive  chemical  mediator  that  triggers
vasodilatation,  modulating  the  course  of
inflammation.
Key words: Submandibular  gland,  2-Thiazolylethylamine,
H1 binding assay, Amylase release, Phosphoinositide hydrol-
ysis,  Nitric  oxide  synthase  activity,  Cyclic  GMP,  Protein
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Introduction
Histamine, one of the autacoids, is primarily stored
and released by mast cells in mammalian tissues and
produces  its  effect  via  interactions  with  histamine
receptor subtypes, the H1, H2, H3 and H4 receptors.1
In  general,  the  interaction  of  histamine  with  H1
receptors causes the contraction of smooth muscle,
and  the  interactions  with  H2 receptors  causes  the
secretion  of  gastric  acid  from  parietal  cells  in  the
stomach and of saliva from acinar cells in the salivary
glands.  H3 receptors  are  localized  as  pre-synaptic
receptors present on histaminergic nerve terminals in
the  central  nervous  system  and  a  wide  variety  of
tissues; they regulate histamine synthesis and release
by a feedback mechanism.2 Moreover, as histamine is
the most abundant agent released during degranula-
tion,  we  suspected  that  it  might  also  mediate  the
effects  of  mast  cells  during  the  bone  resorption
process.3
Histamine receptor subtypes belong to the family
of  receptors  linked  to  different  members  of  the
superfamily of G-protein-coupled receptors. Since in
recent  years  it  is  has  been  found  that  effector
enzymes, such as adenylyl cyclase and phospholipase
C  (PLC),  are  characterized  by  a  large  molecular
heterogeneity,4 the interaction of histamine receptor
subtypes with the intracellular biochemical pathways
is clearly not very straightforward. However, a role for
both  calcium  from  intracellular  stores  and  protein
kinase C (PKC) has been suggested.5
It  has  proposed  that  histamine  is  released  from
mast  cells  by  immunologic  and  non-immunologic
stimuli  during  salivary  gland  inflammation.  As  a
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on H1 and/or H2 receptors on the surface of exocrine
cells, histamine regulates enzyme secretion.6 Emme-
lin7 reported  that  histamine  acted  on  the  sub-
mandibular gland of dogs and cats as a main regulator
of  salivary secretion.8 Furthermore, amylase release
from  rat  parotid  slices  was  stimulated  by  the  H1
histamine  receptor,  as  observed  also  in  guinea  pig
parotid  glands.9 However,  the  receptor-secretory
mechanism,  especially  the  intracellular  signal  trans-
duction,  coupled  to  the  H1 receptor  in  the  rat
submandibular gland has not been studied in detail.
On the other hand, it is described that the nerve
cell bodies of the ganglion located at the hilium of the
rat  submandibular  gland  are  strongly  positive  for
nitric  oxide  synthase  (NOS)  enzyme;10 and  nerve
fibres around acini and ducts are also NOS positive.11
So,  we  want  to  know  whether  the  H1 receptor
stimulation could trigger NOS activation.
The  studies  reported in  the  present  paper  were
directed toward elucidating signal  transduction/sec-
ond  messenger  pathways  within  rat  submandibular
glands associated with 2-thiazolylethylamine (ThEA)-
induced responses through the H1 receptor subtype.
ThEA has been associated with activation of PLC and
PKC, production of nitric oxide (NO) and cyclic GMP
(cGMP),  as  well  as  amylase  release  in  rat  sub-
mandibular glands.
Materials and methods
Histaminergic binding studies
Submandibular microsomal membranes were prepared
from rats as previously reported.12 Briefly, the glands
were excised and immediately homogenized at 4°C in
six  to  eight  volumes  of  50 mM  sodium/potasium
phosphate buffer (pH 7.5), 0.25M sucrose and supple-
mented  with  protease  inhibitors  as  described  else-
where.13 The homogenate was centrifuged at 900 ´ g
twice, and the supernatants collected and spun down
at 10,000 ´ g for 10min and 40,000 ´ g for 60min. The
resulting pellet was resuspended in 50 mM phosphate
(pH 7.5), 5 mM MgCl2 and the same protease inhibitors
to give a final protein concentration of 3–5mg/ml, and
was stored at –80°C untill used. Radioligand binding
assays with the H1 histaminergic antagonist pyrilamine,
[3H]-5-pyridinyl  ([3H]-Pyrilamine;  Dupont  New  Eng-
land Nuclear, Boston, MA, USA), were carried essen-
tially as described elsewhere.12,13 For the dissociation
constant (Kd) and the number of binding sites (Bmax)
calculations, several concentrations of [3H]-Pyrilamine
(0.25–10nM)  were  assessed  using  saturation  iso-
therms.  Membranes  (0.3–0.4mg  of  protein)  were
incubated in duplicate with various concentrations of
[3H]-Pyrilamine. Non-specific binding was determined
in  the  presence  of  10mM  pyrilamine.  Results  were
analysed  with  the  computer-assisted  curve  fitting
program LIGAND.14 All  the experiments  on animals
were conducted in accordance with the Guide for the
Care  and  Use  of  Laboratory  Animals (National
Institutes of Health Publications number 80–23).
Measurement of total labelled inositol
phosphates
Submandibular glands were incubated for 120min in
0.5ml of Krebs Ringer bicarbonate (KRB) gassed with
CO2 in  oxygen  with  37kBq  of  [3H]-myo-inositol
(specific activity 533kBq/mmol) from  Dupont New
England Nuclear. LiCl (10 mM) was added for deter-
mination  of  inositol  monophosphate  accumulation
according  to  the  technique  previously  reported.15
Agonist  was  added  30min  before  the  end  of  the
incubation period and the blockers 30min before the
addition of agonist. Water-soluble inositol phosphates
(IPs) were extracted after 120min incubation follow-
ing the method previously reported.15 Submandibular
gland  slices  were  quickly  washed  with  KRB  and
homogenized in 0.3ml of KRB with 10 mM LiCl and
2ml  of  chloroform/methanol (1:2, v/v)  to stop the
reaction. Then chloroform (0.62ml) and water (1ml)
were added. Samples were centrifuged at 3000 ´ g for
10min,  and  the  aqueous  phase of  the  supernatant
(1–2ml) was applied to a 0.7ml column of Bio-Rad AG
(Formate Form) 1 ´ 8 anion exchange resin (100–200
mesh) suspended in 0.1M formic acid that had been
previously washed with 10 mM Tris–formic (pH 7.4).
The resin was then washed with 20 volumes of 5 mM
myo-inositol followed by six volumes of water, and IPs
were  eluted  with 1M  ammonium  formate in  0.1M
formic acid. One millilitre  fractions were recovered
and  radioactivity  was  determined  by  scintillation
counting. Peak areas were determined by triangula-
tion. Results corresponding to the second peak were
expressed as absolute values of area units under the
curve per milligram  of  tissue wet weight following
the criteria of Simpson’s equation.16 To confirm the
absence of  [3H]-myo-inositol in  the eluted peaks of
IPs,  chromatography  on  silica  gel  60  F254  sheets
(Merk, Buenos Aires, Argentina) was performed using
propan-2-ol/6  N  NH4OH  (14:5)  as  the  developing
solvent following the procedure of Hokin-Neaverson
and Sadeghian.17
PKC activity assay
PKC activity was assayed by measuring the incorpora-
tion  of  32P  from  g-32P-adenosine triphosphate into
histone H1 as previously described.16 Briefly, incuba-
tions were conducted for 30min  at 30°C in a final
volume of 85ml. In the final concentrations, the assay
mixture  contained 25mmol  adenosine triphosphate
(14.8kBq), 10 mM magnesium acetate, 5 mM b-mer-
captoethanol, 50mg of histone H1, 20 mM HEPES (pH
7.4) and, unless otherwise indicated, 0.2 mM CaCl2
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incorporation of  32P phosphate into the histone H1
was  linear  for  at  least  30min.  The  reaction  was
stopped  by  the  addition  of  2ml  of  ice-cold  5%
trichloroacetic acid, 10 mM H3PO4. The radioactivity
retained on GF/c glass-fibre filters after filtration was
determined by counting the filters in 2ml of scintilla-
tion fluid. PKC activity was determined after subtract-
ing the incorporation in the absence of calcium and
phospholipids. The data were expressed in picomoles
of  phosphate  incorporated  into  the  substrate  per
minute per milligram of protein.
NOS activity assay
NOS activity was measured in submandibular glands
of  male  Wistar  rats  using  L-[U-14C]-arginine  as  a
substrate.18 Briefly, submandibular glands were care-
fully dissected and incubated in KRB solution contain-
ing  18.5kBq of  L-[U-14C]-arginine for 20min before
the addition of agonist. When inhibitors were used
they were added from the beginning of the incuba-
tion time at the final concentrations indicated in the
text. The incubations were carried out under a 50%
CO2 in oxygen atmosphere at 37°C and stopped by
homogenization  of  the  glands  in  1ml  of  20 mM
HEPES  (pH  7.4),  0.5 mM EGTA,  0.5 mM  EDTA  and
1 mM  dithiothreitol  at  4°C. The  supernatants  were
passed through 2ml of Dowex AG-50 WX-8 columns,
and  L-[U-14C]-citrulline  was  eluted  with  water  and
quantified as described previously.12 NOS activity was
inhibited more than 90% by 0.5 mM NG-monomethyl-
L-arginine (L-NMMA). In  the experiments with NOS
activation by the agonist, we chose lower concentra-
tions of this arginine analogue to inhibit the effects in
order not to modify the basal NOS activity.
cGMP assay
Glands  were  incubated  in  1ml  of  KRB  containing
0.1 mM isobuthyl methyl xantine for 30min under a
constant current of 5% CO2 in oxygen. The agonist was
added in the last 10min while inhibitors were included
in the incubation volume from the beginning. Reac-
tions were stopped by homogenization as previously
stated,12 and samples were assayed by radioiummu-
noassay using [125I]-cGMP from Dupont New England
Nuclear  (81400kBq/mmol)  and  anti-cGMP  antisera
from Sigma Chemical Co. (St Louis, MO, USA).
Determination of amylase activity
Submandibular gland slices (5.1 ± 0.5mg) were used
throughout.  Free  connective  tissue,  fat  and  lymph
nodes were gently remove under a magnifying glass,
slices were placed in tubes containing 500ml of KRB
solution  containing  116 mM  NaCl,  5.4 mM  KCl,
0.8 mM MgSO4, 1.8 mM CaCl2, 0.96 mM NaH2PO4,
25 mM  NaHCO3 and  5 mM  b-hydroxybutyric  acid
(pH 7.4), and were then bubbled with 95% O2 and 5%
CO2 at 37°C. After an equilibrium period of 10min,
vehicle (basal values) or drugs to be evaluated (one
concentration in each tube) were added and allowed
to  stay  for  20min,  after  which  the  total  amylase
content  or  that  released  into  the  medium  was
determined by the method described by Bernfeld19
using starch suspension as the substrate.
Drugs
ThEA (H1 receptor agonist), L-NMMA (NOS inhibitor),
L-arginine (natural substrate of NOS), verapamil (cal-
cium  blocker),  staurosporine  (PKC  inhibitor),  tri-
fluoperazine  (TFP)  (calcium/calmodulin  inhibitor),
pyrilamine maleate (H1 receptor antagonist), cimeti-
dine  (H2 receptor  antagonist)  (all  Sigma  Chemical
Co.),  1-[6(17b)-3-methoxyestra-1,3,5(10)-trien-17-yl]
amino  hexyl-1H-pyrrole-2,5  dione  (U-73122)  (PLC
inhibitor) (ICN Pharmaceuticals Inc., Costa Mesa, CA,
USA) and [1H]-(1,2,4)-oxadiazola-(4,3–2)-quinoxaline-
1-one  (ODQ)  (soluble  guanylate  cyclase  inhibitor)
(Tocris  Cookson  Inc.,  Ellisville,  MO,  USA)  stock
solutions were freshly prepared in the corresponding
buffers. The drugs were diluted in the bath to achieve
the final concentrations stated in the text.
Statistical analysis
Student’s  t-test  for  unpaired  values  was  used  to
determine the levels of significance. When multiple
comparison were necessary, after analysis of variance,
the Student–Newman–Keuls test was applied. Differ-
ences between means were considered significant if p
< 0.05.
Results
To  assess  the  expression  of  histamine  H1 receptor
subtype in the rat submandibular gland, a radioligand
binding  assay  was  performed.  [3H]-Pyrilamine
revealed a single  class  of  high-affinity  binding  sites
demonstrable by Scatchard analysis of the saturation
curve (Table 1).
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Table 1. Specific [
3H]-Pyrilamine binding to submandibular
gland membranes
Radioligand Bmax (fmol/mg protein) Kd (nM)
[
3H]-Pyrilamine 96.5 ± 8.1 3.66 ± 0.41
The membranes from rat submandibular glands were prepared for
binding assays as stated in Materials and methods. The number of
binding  sites  (Bmax) and the equilibrium dissociation  constant  (Kd)
were analysed using weighted non-linear regression, computerized
least-squares curve-fitting programs (LIGAND).14 Values prsented as
the  mean  ±  SEM  of  at  least  four  experiments  performed  in
duplicate.To  verify  whether  the  H1 receptor  subtype  was
coupled  to  phosphoinositide  turnover  in  the  rat
submandibular  gland,  the  effect  of  ThEA  on  IP
accumulation, in the presence or absence of histami-
nergic antagonists, was investigated. As can be seen in
Fig.  1, ThEA  (1 ´ 10–7 M)  increased  IP  formation,
pyrilamine  (1  ´ 10–6M)  but  not  cimetidine  (1  ´
10–6 M) significantly inhibited the stimulatory action
of ThEA, pointing to the participation of H1 receptor
activation by ThEA upon IP accumulation.
To determine the participation of PLC in the effect
of ThEA, the action of U-73122 was explored. As can
be seen in Fig. 1, U-73122 (5 ´ 10–6M) blunted the
effect of ThEA. As can be seen in Fig. 2, ThEA was also
able to translocate PKC from the glandular cytosol to
the  glandular  membrane;  this effect  was  also  abro-
gated by the specific H1 antagonist.
To know whether the endogenous NO signalling
system  was  turned  on  in  the  ThEA-activated  H1
receptor on the rat submandibular gland, NOS activ-
ity in the presence of ThEA was explored. As can be
seen in Fig.  3, there was a concentration-depended
increase in NOS activity; the maximal effect being at
1 ´ 10–7 M, a concentration that was active on both
IP  accumulation  and  PKC  translocation. The  incre-
ment of NOS activity was blunted by  L-NMMA (5 ´
10–5 M), a reversible NOS inhibitor, while the natural
substrate L-arginine (5 ´ 10–4M) reversed this inhibi-
tion (Fig. 3).
To study the nature of the mechanism by which
the activation of H1 receptor increased NOS activity
and  cGMP  production,  rat  submandibular  glands
were  incubated  with  several  inhibitors.  Table  2
shows  that  pyrilamine  inhibited  the  stimulatory
action  of  ThEA  on  both  NOS  activity  and  cGMP
production. Also, the inhibition of the calcium influx
by verapamil (5 ´ 10–6M), of calcium/calmodulin by
TFP  (5  ´ 10–6 M)  and  of  NOS  by  L-NMMA  (5  ´
10–5 M) attenuated the H1-receptor-dependent activa-
tion of NOS activity and cGMP accumulation. Moreo-
ver,  the  inhibitory  action  of  L-NMMA on  the ThEA
effect  upon  NOS  and  cGMP  was  reversed  by
L-arginine (5 ´ 10–4M) (Table 2). A selective inhibitor
of NO-sensitive guanylate cyclase, ODQ was able to
blunt  the  stimulatory  action  of ThEA  upon  cGMP
accumulation. Additionally, the inhibition of PKC by
staurosporine  (1  ´ 10–9M)  increased  both,  NOS
activity  and  cGMP production.  None of  the  inhibi-
tors had any  effect  per  se on  basal  values  of  NOS
activity and cGMP levels (data not shown) with the
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FIG.  1.  ThEA  action  on  the  accumulation  of  IPs  of  rat
submandibular gland slices.  The effect  of  the H1 receptor
agonist (1 ´ 10
–7M) ThEA alone (B), or in the presence of the
H1 receptor antagonist (1 ´ 10
–6 M) pyrilamine (C), or the H2
receptor antagonist (1 ´ 10
–6 M) cimetidine (D), and the PLC
inhibitor (5 ´ 10
–6M) U-73122 (E) above basal values (A) was
analysed. Results presented as the mean ± SEM of seven
experiments performed in duplicate in each case.  * Differ
significantly from (A) with p < 0.001.
FIG.  2.  Activation  by  ThEA  of  PKC.  PKC  activity  was
determined  in  both  the  membrane  and  cytosol  of  rat
submandibular gland slices.  The effect  of  the H1 receptor
agonist (1 ´ 10
–7M) ThEA alone (B), or in the presence of the
H1 receptor  antagonist  (1 ´ 10
–6M)  pyrilamine  (C)  above
basal  values  (A)  was  analysed.  Results  presented  as  the
mean ± SEM of six experiments performed in duplicate in
each case. * Differ significantly from (A) with p < 0.001.
FIG.  3.  ThEA  action  on  NOS  activity.  Rat  submandibular
gland slices were incubated with different concentrations of
the  H1 receptor  agonist  ThEA  in  the  absence  (d )  or  the
presence  (m )  of  the  NOS  inhibitor  L-NMMA  (5 ´ 10
–5 M).
Reversal of inhibition by a natural NOS substrate L-arginine
(5 ´ 10
–4M)  (h )  and  basal  values  (B)  are  shown.  Values
presented  as  the  mean  ±  SEM  of  eight  experiments  per-
formed in duplicate.exception  of  L-NMMA,  which  at  the  concentration
used decreased in 75% the NOS activity and cGMP
production.
In  addition,  the  generation  of  amylase  from  rat
submandibular  slices  was  dose-dependently  stimu-
lated by ThEA (Fig. 4). The effect of ThEA on amylase
release  was  inhibited  by  pyrilamine  but  not  by
cimetidine.  L-NMMA did not have an effect on ThEA-
amylase release (Fig. 4). These results suggest that the
stimulatory  effect  of  ThEA  on  amylase  release  is
mediated directly by the H1 receptor and independ-
ently of NOS activation.
Discussion
These data provide important new insights into the
pathways by which the histaminergic system induces
rapid activation of NOS with subsequent accumula-
tion  of  cGMP. These  intracellular  signals  were  not
directly associated with the capacity of the system to
release amylase. However, both effects (amylase and
NO releases) were triggered by the activation of the
H1 receptor subtype as ThEA (a specific H1 agonist)
and pyrilamine (a specific H1 antagonist) exerted and
blocked these effects, respectively.
Histaminergic systems activation in submandibular gland
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Table 2. Effect of ThEA upon NOS activity and cyclic GMP accumulation of rat submandibular
gland slices: influences of different inhibitory agents
Additions NOS activity
(pmol/g tissue wet weight)
cGMP
(pmol/g tissue wet weight)
None 450 ± 26 18 ± 1
ThEA 732 ± 32* 41 ± 4*
pyrilamine + ThEA 470 ± 28 22 ± 2
Verapamil +ThEA 490 ± 30 20 ± 3
TFP +ThEA 380 ± 21 17 ± 2
Staurosporine +ThEA 920 ± 37* 58 ± 2*
L-NMMA +ThEA 280 ± 12 11 ± 1
L-NMMA + ThEA + L-arginine 686 ± 29* 43 ± 3*
ODQ + ThEA – 21 ± 2
NOS activity and cGMP accumulation were measured by incubating rat submandibular gland slices with or
without inhibitory agents for 20min and then for an additional 10min with the H1 receptor agonist (1 ´ 10–7 M)
ThEA. Results presented as the mean ± SEM of seven experiments performed in duplicate in each group. The
final concentrations of the inhibitors were: pyrilamine (H1 receptor antagonist), 1 ´ 10–6M; verapamil (calcium
blocker) and TFP (calcium/calmodulin blocker), 5 ´ 10–6 M; staurosporine (PKC inhibitor), 1 ´ 10–9 M; L-NMMA
(NOS inhibitor), 5 ´ 10–5 M; L-arginine (natural NOS substrate), 5 ´ 10–4 M; and ODQ (soluble guanylate cyclase
inhibitor), 5 ´ 10–6 M. * Significantly different from basal values (none) with p < 0.001.
FIG. 4. (a) Effect of the H1 receptor antagonist (1 ´ 10
–6M) pyrilamine (h ) on the dose–response curve of the H1 receptor agonist
ThEA (d ) upon amylase release by rat submandibular gland slices. Tissues were incubated for 30min in the presence or
absence of H1 receptor antagonist, and the the dose–response curves to ThEA were obtained. Values presented as the mean
± SEM of seven experiments in each group. (b) Effect of the H1 receptor agonist (1 ´ 10
–7M) ThEA alone (B), or in the presence
of the H1 receptor antagonist (1 ´ 10
–6M) pyrilamine (C), the H2 receptor antagonist (1 ´ 10
–6M) cimetidine (D), and the NOS
inhibitor (5 ´ 10
–5M) L-NMMA (E) upon basal values (A). Values presented as the mean ± SEM of eight different determinations
in each group. Tissues were incubated for 30min in the presence of different inhibitors and then ThEA was added. Values are
expressed as percentage changes calculated by comparison with the absolute values prior to the addition of ThEA. * Differ
significantly from (A) and ** differ significantly from (B), with p < 0.001.Our  results  support  the  assumption  that  ThEA-
promoted increases in NO and cGMP are mediated by
H1 receptors: first, because this subtype is expressed
in submandibular gland membranes, as was demon-
strated by  the binding  assay; and, second, because
pyrilamine was able to inhibit both NO production
and cGMP accumulation. It is important to note that
specific  pyrilamine binding  to H1 receptors in sub-
mandibular gland membranes was saturable and best
described  by  interaction  of  the  radioligand  with  a
single class of high-affinity binding sites.
The participation of constitutive NOS was demon-
strated  by  the  ability  of  the  stereospecific  NOS
inhibitor L-NMMA20 to inhibit the ThEA-induced NOS
activity  and  cGMP  accumulation  in  the  rat  sub-
mandibular  gland. These was  further  confirmed  by
the  reversibility  of  the  action  of  L-NMMA  by  the
natural  substrate  L-arginine. A  relationship  between
histamine and NO has been reported,21,22 but little is
known  about  the  mechanism  by  which  histamine
control NOS activity in the submandibular gland.
Among  the  mechanisms  involved  in  the
H1-receptor-dependent activation of NOS is the stim-
ulation of soluble guanylate cyclase to increase the
accumulation  of  cGMP.  The  fact  that  a  selective
inhibitor of NO-sensitive guanylate cyclase23 was able
to prevent the ThEA H1-receptor activation of cGMP
production confirms this assumption. This is similar
to  the  effect  of  other agonists,24,25 suggesting  that
some  of  the  physiological  effects  of  NO  may  be
mediated  by  the  activation  of  soluble  guanylate
cyclase. NO and cGMP have been suggested to act in
salivary vasoregulation by  several investigators. The
vessels  of  submandibular26,27 and  parotid28 glands
exhibit a NO-dependent basal vasodilator tone. There-
fore, the vasculature of  the submandibular  gland is
highly responsive to exogenous NO. cGMP appears to
regulate amylase release of the mouse parotid gland
via  a  cGMP-dependent kinase,29 but  did  not  affect
amylase release by the rat parotid gland linked to a
soluble guanylate cyclase.30
ThEA increased accumulation of IPs and this action
was inhibited by pyrilamine, suggesting the involve-
ment  of  an  H1 receptor,  while  the  H2 receptor
antagonist, cimetidine, was without effect. This ThEA
action  was  linked  to  PLC  as  the  enzyme  inhibitor
U-73122 abrogated this effect. It is known that PLC
hydrolysis of submandibular gland membrane phos-
phoinositides generates the intracellular second mes-
sengers  diacyglycerol  and  inositol  triphosphate,
which activate PKC and calcium/calmodulin, respec-
tively.  Our  results,  however,  indicate  that  inter-
mediates  of  phosphoinositide  hydrolysis  oppose
ThEA-induced NOS activation. Thus, rapid activation
of  the  enzyme  is  related  to  calcium  mobilization,
while inhibition of NOS requires extensive transloca-
tion of PKC. This is based on the observed potentation
by  staurosporine  and  the  inhibition  by  TFP  and
verapamil on  the effect  of ThEA on glandular  NOS
activity  and  cGMP  production.  H1 receptors  are
classically linked  to activation of PKC,31,32 and the
regulatory role for protein phosphorylation of NO by
PKC  and  calcium/calmodulin-dependent  kinase  has
been demonstrated.33–35
Moreover, ThEA caused translocation of PKC from
the cytosol to cell membrane in the rat submandibular
gland  as  it  does  in  airway  epithelium36 and  in
neuroblastoma  NCB-20  cells.37 We  did  not  look
specifically at the PKC wing of PLC activation in this
work,  but  it  is  possible  that  activation  of  cell-
H1-receptor-specific isoforms of PKC may also occur
in  rat  submandibular  glands  in  response  to ThEA-
induced activation of PLC.
The  receptor-secretory  mechanism  of  ThEA-
induced  amylase  release  in  the  rat  submandibular
gland is mediated directly and selectively by the H1
receptor. However, with present results there is no
evidence supporting such a role of the L-arginine/NO
pathway in regulating amylase secretion.
The vasculature of the submandibular gland exhib-
its a NO-dependent basal vasodilator tone.26,27 Also,
the vasculature of these tissues is highly responsive to
exogenous NO. Therefore, the release of endogenous
NO by histamine during the first step of inflammation
may  be  triggered  by  vasodilation  modulating  the
course of inflammation.
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Notes
ThEA 2-thiazolylethylamine
PKC Protein Kinase C
NOS Nitric Oxide Synthase
NO Nitric Oxide
cGMP Cyclic GMP
KRB Krebs Ringer Bicarbonate
L-NMMA NG-monomethyl-L-arginine
PLC Phospholipase C
IPs Inositol Phosphates
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